Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018

information fournie par Boursorama •17/05/2018 à 07:30

Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018

Strasbourg, France, May 17, 2018, 7:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that new clinical data on the oncolytic virus Pexa-Vec will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting, taking place from 1 to 5 June in Chicago.

These results were obtained from a clinical (“neoadjuvant”) study that evaluated the biological effects of pre-operative intravenous (IV) administration of Pexa-Vec in patients with locally advanced or metastatic cancers, prior to planned surgical resection. University of Leeds (United Kingdom) is the sponsor of this trial that was supported by Transgene.

.../...